On Thursday, July 23rd, 2026, a panel of federal health advisers recommended easing access to several injectable peptides, including BPC-157, TB-500, and KPV, which have gained popularity among wellness influencers and celebrities. The advisory group voted 8-6, with one abstention, in favor of adding these peptides to the FDA’s list of substances considered safe for pharmacy compounding, effectively advising the agency to drop current restrictions barring pharmacies from producing them.

The panel’s vote is not binding but is expected to support Health Secretary Robert F. Kennedy Jr., who has expressed strong support for peptides and aims to overturn restrictions established under the previous administration.

The vote followed the addition of more than half a dozen panel members with ties to the peptide industry, including doctors, pharmacists, and consultants. David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, said after the vote on BPC-157, “I voted yes because it’s time to put this decision back in the hands of the patient, the physician and the pharmacist.”

However, the decision faced criticism from FDA staff scientists who highlighted the lack of sufficient data proving the safety and efficacy of these peptides for medical use. Dr. Elizabeth Rebello of the University of Texas MD Anderson Center expressed concern, stating, “I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science.”

If the FDA follows the panel’s recommendation, telehealth companies are expected to increase marketing of these peptides for wellness and cosmetic purposes.

Sources